MA52032A - Régulateurs de nrf2 - Google Patents

Régulateurs de nrf2

Info

Publication number
MA52032A
MA52032A MA052032A MA52032A MA52032A MA 52032 A MA52032 A MA 52032A MA 052032 A MA052032 A MA 052032A MA 52032 A MA52032 A MA 52032A MA 52032 A MA52032 A MA 52032A
Authority
MA
Morocco
Prior art keywords
nrf2 regulators
nrf2
regulators
Prior art date
Application number
MA052032A
Other languages
English (en)
Inventor
Jeffrey Charles Boehm
James Francis Callahan
Thomas Daniel Heightman
Jeffrey K Kerns
Alison Jo-Anne Woolford
Hongxing Yan
Original Assignee
Astex Therapeutics Ltd
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd, Glaxosmithkline Ip Dev Ltd filed Critical Astex Therapeutics Ltd
Publication of MA52032A publication Critical patent/MA52032A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
MA052032A 2015-06-15 2016-06-15 Régulateurs de nrf2 MA52032A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562175505P 2015-06-15 2015-06-15

Publications (1)

Publication Number Publication Date
MA52032A true MA52032A (fr) 2021-01-20

Family

ID=56178402

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052032A MA52032A (fr) 2015-06-15 2016-06-15 Régulateurs de nrf2

Country Status (11)

Country Link
US (2) US10272095B2 (fr)
EP (2) EP3766878B1 (fr)
JP (1) JP6786527B2 (fr)
KR (1) KR20180018684A (fr)
CN (1) CN108137557B (fr)
AU (1) AU2016280236B2 (fr)
CA (1) CA2988374A1 (fr)
ES (2) ES2910938T3 (fr)
MA (1) MA52032A (fr)
RU (1) RU2018101080A (fr)
WO (1) WO2016203401A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3782996T1 (sl) 2015-06-15 2024-06-28 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulatorji
EP3766878B1 (fr) 2015-06-15 2022-03-16 GlaxoSmithKline Intellectual Property Development Limited Régulateurs de nrf2
WO2017060855A1 (fr) * 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Pyrazoles d'arylcyclohéxyle utilisés en tant que régulateurs de nrf2
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
CN108779108A (zh) * 2016-12-06 2018-11-09 葛兰素史密斯克莱知识产权发展有限公司 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
CA3044773A1 (fr) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Activateurs nrf2
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
WO2018211474A1 (fr) 2017-05-19 2018-11-22 Trudell Medical International Dispositif à pression expiratoire positive
WO2019116231A1 (fr) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Activateur de nrf2 pour le traitement d'une lésion pulmonaire aiguë, d'un syndrome de détresse respiratoire aiguë et d'un syndrome de dysfonction d'organes multiples
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
JP2021524469A (ja) * 2018-05-23 2021-09-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２アクチベーターとしてのインダン
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
NZ776102A (en) 2018-12-05 2024-12-20 Scohia Pharma Inc Macrocyclic compound and use thereof
JP7602469B2 (ja) * 2019-02-15 2024-12-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン
MX2021014680A (es) 2019-05-31 2022-04-06 Ube Corp Derivado de benzotriazol.
CN113519459B (zh) * 2021-06-11 2022-03-25 中国科学院合肥物质科学研究院 一种采用调节肝细胞ros水平的磁场发生装置在调节人/鼠肝细胞氧化应激中的应用
US20250296939A1 (en) * 2022-04-28 2025-09-25 Kyoto Pharmaceutical Industries, Ltd. Benzothiophene compound
JP7605446B2 (ja) 2022-04-28 2024-12-24 第一三共株式会社 ベンゾトリアゾール化合物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB348944A (en) * 1930-07-05 1931-05-21 Ig Farbenindustrie Ag Improvements in the concentration of aqueous formic acid
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
EP0570594B1 (fr) 1991-12-10 1997-07-30 Shionogi & Co., Ltd. Derive d'acide hydroxamique a base de sulfonamide aromatique
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
WO2002080899A1 (fr) 2001-03-30 2002-10-17 Eisai Co., Ltd. Agent de traitement de maladie digestive
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20040157919A1 (en) 2002-01-25 2004-08-12 Yong-Qian Wu Trisubstituted carbocyclic cyclophilin binding compounds and their use
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
JPWO2004007464A1 (ja) 2002-07-10 2005-11-10 住友製薬株式会社 イミダゾール誘導体
US7589116B2 (en) 2003-04-03 2009-09-15 Merck & Co. Inc. Biaryl substituted pyrazoles as sodium channel blockers
WO2006044133A1 (fr) 2004-09-24 2006-04-27 Axys Pharmaceuticals, Inc. Inhibiteurs de la tryptase, contenant de la cetone active
JP5000490B2 (ja) 2005-04-28 2012-08-15 武田薬品工業株式会社 チエノピリミドン化合物
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
WO2008002490A2 (fr) 2006-06-23 2008-01-03 Radius Health, Inc. Traitement de symptômes vasomoteurs par des modulateurs des récepteurs d'œstrogène sélectifs
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
CA2729767A1 (fr) 2008-07-07 2010-01-14 Fasgen, Inc. Nouveaux composes, compositions pharmaceutiques les contenant, et leurs procedes d'utilisation et de preparation
RU2486253C2 (ru) 2008-07-25 2013-06-27 Инфоком Корпорейшн Онкоген nrf2 и его применение
KR20110133034A (ko) 2009-02-26 2011-12-09 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
WO2013122028A1 (fr) 2012-02-13 2013-08-22 武田薬品工業株式会社 Composé à noyaux aromatiques
WO2013155528A2 (fr) 2012-04-13 2013-10-17 Fasgen, Inc. Méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides
US20160046616A1 (en) 2013-03-15 2016-02-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
KR102301867B1 (ko) 2013-12-18 2021-09-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
WO2015138220A1 (fr) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih
WO2015135091A1 (fr) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih
CA2988373A1 (fr) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Regulateurs de nrf2
SI3782996T1 (sl) 2015-06-15 2024-06-28 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulatorji
EP3766878B1 (fr) 2015-06-15 2022-03-16 GlaxoSmithKline Intellectual Property Development Limited Régulateurs de nrf2
WO2017060855A1 (fr) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Pyrazoles d'arylcyclohéxyle utilisés en tant que régulateurs de nrf2
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
CN108779108A (zh) 2016-12-06 2018-11-09 葛兰素史密斯克莱知识产权发展有限公司 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
JP2020502136A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのビスアリールアミド
EP3555068B1 (fr) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited Composés de 3-oxo-1,4-diazepinyle comme activateurs de nrf2
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２アクチベーターとしてのビスアリール複素環

Also Published As

Publication number Publication date
US20190224212A1 (en) 2019-07-25
KR20180018684A (ko) 2018-02-21
JP2018517730A (ja) 2018-07-05
US10272095B2 (en) 2019-04-30
ES2910938T3 (es) 2022-05-17
EP3766878A1 (fr) 2021-01-20
CN108137557A (zh) 2018-06-08
WO2016203401A1 (fr) 2016-12-22
JP6786527B2 (ja) 2020-11-18
CN108137557B (zh) 2021-09-07
RU2018101080A3 (fr) 2019-07-17
BR112017027137A2 (pt) 2018-08-14
AU2016280236A1 (en) 2017-12-21
EP3307729A1 (fr) 2018-04-18
AU2016280236B2 (en) 2019-02-07
HK1256199A1 (zh) 2019-09-13
US20180169110A1 (en) 2018-06-21
EP3307729B1 (fr) 2020-09-02
CA2988374A1 (fr) 2016-12-22
US10485806B2 (en) 2019-11-26
ES2834490T3 (es) 2021-06-17
RU2018101080A (ru) 2019-07-15
EP3766878B1 (fr) 2022-03-16

Similar Documents

Publication Publication Date Title
NO2025024I1 (no) Elranatamab
NL301311I2 (nl) sugemalimab
FIC20240028I1 (fi) Retifanlimabi
NO2023005I1 (no) tirzepatide
NO2023007I1 (no) Vutrisiran
MA52309A (fr) Régulateurs de nrf2
MA52032A (fr) Régulateurs de nrf2
DK3305788T3 (da) Janus-kinase-hæmmer
EP3290364A4 (fr) Système de surveillance d'usure de bande transporteuse
DE112015006486A5 (de) Inkubationsrinne
FI20155933A (fi) Kaksikomponenttinen aerosoliformulaatio
DE102015206660A8 (de) Plattenaufteilanlage
DE112015005906A5 (de) Gurtschlossbringer
ES1138645Y (es) Pieza enroscada
EP3307242A4 (fr) Picn-01
ITUB20153203A1 (it) Fioriera
DE102015000551A8 (de) Rotationszerstäuberturbine
EP3392310A4 (fr) Composition de polyoxyde alkylène
FI11070U1 (fi) Kantojyrsin
DE102015226549B8 (de) Hybridheizmodul
FI11075U1 (fi) Poijukori
UA32871S (uk) Секатор
CU20150012S4 (es) Tenaza de soldar
NO20151704A1 (no) Skvettern
FI11104U1 (fi) Kairauskone